Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatologic therapeutics: thalidomide. A practical guide.

M Rosenbach1, Victoria P Werth

  • 1Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19119, USA.

Dermatologic Therapy
|November 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of CB2R Activation on Inflammatory Pathways in Dermatomyositis.

Biomedicines·2026
Same author

Prednisone dosage is the primary modifiable risk factor for infection in pemphigus with rituximab treatment: A retrospective analysis of 105 patients.

Journal of the American Academy of Dermatology·2026
Same author

Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.

Clinical, cosmetic and investigational dermatology·2026
Same author

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding.

Frontiers in immunology·2026
Same author

Evaluation of the applicability of the Cutaneous Lupus Erythematosus Area and Severity Index in Filipino cutaneous lupus erythematosus patients.

JAAD international·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles

Thalidomide, initially withdrawn due to birth defects, resurged due to its anti-inflammatory properties. Dermatologists can now safely use thalidomide for various skin conditions.

Area of Science:

  • Dermatology
  • Pharmacology
  • Teratology

Background:

  • Thalidomide's initial introduction in the 1950s was followed by widespread use, leading to severe birth defects and market withdrawal in the 1960s.
  • A serendipitous discovery during erythema nodosum leprosum treatment revealed thalidomide's potent anti-inflammatory effects, prompting renewed interest in its therapeutic potential.

Purpose of the Study:

  • To provide a comprehensive review of thalidomide, covering its history, pharmacology, and mechanisms of action.
  • To guide dermatologists on the safe and effective use of thalidomide for cutaneous diseases, including off-label applications.

Main Methods:

  • Review of historical data and scientific literature on thalidomide.
  • Analysis of pharmacological properties and mechanisms of action.

Related Experiment Videos

  • Compilation of information on dermatologic applications and safety monitoring.

    • Main Results:

    • Thalidomide, despite its teratogenic history, possesses significant anti-inflammatory properties.
    • The drug has emerged as a viable treatment option for several dermatologic conditions.
    • Understanding its pharmacology and mechanisms is crucial for safe clinical application.

    Conclusions:

    • Thalidomide's complex history necessitates careful consideration for its therapeutic use.
    • This review equips dermatologists with the knowledge to safely prescribe and monitor thalidomide for cutaneous diseases.
    • Further research into thalidomide's applications and safety profile in dermatology is warranted.